Inhaler devices in asthma and COPD - An assessment of inhaler technique and patient preferences
Inhaler devices in asthma and COPD - An assessment of inhaler technique and patient preferences
复制标题
DOI：
10.1016/j.rmed.2014.04.019
复制
发表时间：
2014-07-01
影响因子：
4.3
通讯作者：
Fonseca, Joao A.
中科院分区：
文献类型：
--
作者：
Chorao, Pedro;Pereira, Ana M.;Fonseca, Joao A.
背景：吸入器装置的不正确使用仍然是呼吸系统疾病管理的障碍。我们的目的是评估吸入器技术错误的频率;确定被认为是最容易和最喜欢使用的设备;研究设备类型、人口统计学和患者偏好与吸入器技术（IT）的关联。对301名患有哮喘（194名）或慢性阻塞性肺疾病的成年人进行横断面评估，这些人接受了Aerolizer（（R））、Autohaler（（R））、Breezehaler（（R））、Adhus（（R））、Handihater（（R））、不带隔离器的MDI、Miat-haler（（R））、Novolizer（（R））、Respimat（R））和/或Turbohaler（R））。患者完成自我评估问卷和面对面访谈，并演示吸入器技术。错误步数率（错误步数除以总步数; RWS）是主要结局。计算了呈现>=1 IT错误的调整后比值比（aOR）（95%置信区间[CI]）。结果：根据464项吸入器技术性能，中位RWS为18%。Turbohaler（（R））（21%）和Turbohalus（（R））（19%）被选为最简单的，Novolizer（（R））（18%），Turbohaler（（R））（17%）被选为日常使用的首选。女性（aOR 2.68 [95% CI 1.55-4.65]; vs.男性），>64岁患者（aOR 2.73 [95% CI 1.15-6.48]; vs.
Background: Incorrect use of inhaler devices remains an obstacle for respiratory diseases management. We aimed to evaluate the frequency of inhaler technique errors; to determine the devices perceived as the easiest and favourite to use; to study the association of device type, demographics and patient preferences with inhaler technique (IT).Methods: Cross-sectional assessment of 301 adults, with asthma (194) or chronic pulmonary obstructive disease, undergoing treatment with Aerolizer((R)), Autohaler((R)), Breezehaler((R)), Diskus((R)), Handihater((R)), MDI without spacer, Miat-haler((R)), Novolizer((R)), Respimat((R)) and/or Turbohaler((R)). Patients completed self-assessment questionnaires and face-to-face interview, with demonstration of inhaler technique. The rate of wrong steps (number of wrong steps divided by number of total steps; RWS) was the primary outcome. Adjusted odds ratio (aOR) (95% confidence intervals [Cl]) for presenting >=1 IT errors were computed.Results: From the 464 inhaler technique performances, the median RWS was 18%. Turbohaler((R)) (21%) and Diskus((R)) (19%) were chosen as easiest and Novolizer((R)) (18%), Diskus((R)) (18%), Turbohaler((R)) (17%) as favourite for daily use. Females (aOR 2.68 [95% CI 1.55-4.65]; vs. males], patients with >64 yr (aOR 2.73 [95% CI 1.15-6.48]; vs